Invitation to HMS Networks’ second quarter conference call 2025 HMS Networks AB (publ) will release its second quarter report of 2025 on Friday July 11th, 2025, at 07.30 AM CEST. On the same day, at 09.00 AM CEST, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts. The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. If you wish to participate via webcast, please use the link below. If...
Inbjudan till HMS Networks telefonkonferens för det andra kvartalet 2025 HMS Networks AB (publ) offentliggör sin rapport för det andra kvartalet 2025 fredagen den 11 juli 2025 klockan 07.30. Samma dag klockan 09.00 arrangeras en telefonkonferens för press och aktiemarknad, där VD och koncernchef Staffan Dahlström samt finanschef Joakim Nideborn presenterar rapporten. Presentationen hålls på engelska och följs direkt via telefon eller via internet. De bilder som används under presentationen kommer finnas tillgängliga på HMS webbplats före telefonkonferensen. Om du önskar delta via webcast...
While implied guidance for H1 revenues is ~1–4% below our forecast and consensus, the underlying sequential performance is directionally in line with the broader set of peers to have reported to date. We find this growth and gross margin profile solid, given we are at the tail-end of the life of Nordic’s 10-year-old 55nm technology platform. Combined with the arguably unprecedented level of uncertainty for the company’s customers, we find it achieving a ~50% gross margin and accelerated Cellular...
A director at Nordic Semiconductor ASA bought 20,090 shares at 102.500NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.